期刊文献+

晚期恶性肿瘤合并脓毒血症病人血浆TFPI及TF含量的变化 被引量:2

The Oberservation on Levels of TFPI and TF in Advanced Malignancy Patients with Sepsis
下载PDF
导出
摘要 目的观察晚期恶性肿瘤合并脓毒血症患者血浆组织因子途径抑制物(TFPI)、组织因子(TF)含量的变化及其与严重感染的关系。方法用酶联免疫吸附法测定TFPI、TF含量。结果与正常对照组比较,晚期恶性肿瘤非感染组血浆中TFPI、TF抗原含量升高(P<0.05),感染组TFPI、TF抗原含量明显升高(P<0.01);与晚期恶性肿瘤非感染组比较,晚期恶性肿瘤感染组TFPI、TF抗原水平升高(P<0.05)。结论晚期恶性肿瘤合并脓毒血症病人在感染早期TFPI、TF抗原含量比非感染期进一步升高,有利于肿瘤患者合并严重感染的早期判断。 Objective To observe the changes of plasma tissue tactor pathway mntntor(TPFI) and tissue factor TF in the advanced malignancy patients with sepsis and the relation of TFPI and TF with the infection and its degree. Metheds TFPI and TF antigens were measured by ELISA assay. Results Both in non-sepsis group and sepsis group of advanced stage malignancy,the level of TFPI and TF antigen were significantly higher than that in normal reference group(P〈0. 05). There was significant difference for TFPI and TF antigen in non-sepsis and sepsis group of advanced stage malignancy(P〈0.05). Conclusion The TFPI and TF antigen levels in patients of advanced malignancy with sepsis were significantly higher than that in non-sepsis group of advanced malignancy, Which is beneficial to diagnose early of sepsis for the patients of advanced malignancy.
出处 《江西医学院学报》 CAS 2005年第5期18-20,共3页 Acta Academiae Medicinae Jiangxi
基金 江西省卫生厅课题
关键词 组织因子途径抑制物 组织因子 脓毒血症 晚期恶性肿瘤 tissue factor pathway inhibitoy(TFPI) tissue factor(TF) sepsis advanced malignancy
  • 相关文献

参考文献10

  • 1叶任高.内科学[M](第5版)[M].北京:人民卫生出版社,2000.313.
  • 2Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/AT/SIS international sepsis definitions conference[J].Crit Care Med,2003,31:1 250-1 256.
  • 3刘伟,朱广瑾.组织因子途径抑制物-1与临床疾病的相关性研究[J].国外医学(输血及血液学分册),2004,27(3):216-219. 被引量:5
  • 4Hansen JB,Svensson B,Olsen R,et al.Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro[J].Thrombosis and Haemostosis,2000,83:937-943.
  • 5Versteeg HH,Peppelenbosch MP,Spek CA.The pleiotropic effects of tissue factor:a possible role for factor Ⅶa-induced intracellular signaling[J]. Thromb Haemost,2001,86:1 353-1 359.
  • 6Ruf W,Fischer EG,Huang HY,et al.Diverse functions of protease receptor tissue factor in inflammation and metastasis[J].Immunol Res,2000,21:289-292.
  • 7刘国勋,李 杰,杨 勤,陈 玲,谢朝阳,凌光鑫.恶性肿瘤患者血浆TFPI抗原及其活性测定的临床意义[J].实用肿瘤杂志,1999,14(4):219-221. 被引量:1
  • 8叶玲丽,陈萍.中晚期肿瘤患者围术期血浆TF和TFPI水平变化及意义[J].江西医学检验,2004,22(2):123-124. 被引量:4
  • 9Zhang Y,Deng Y,Luther T,et al.Tissue factor controls the balance of angiogenic and antiangiogeic properties of tumor cell in mice[J].J Clin Invest,1994,94(3):1 320-1 627.
  • 10周业江,时德.组织因子与肿瘤研究进展(文献综述)[J].国外医学(外科学分册),2001,28(5):264-267. 被引量:9

二级参考文献65

  • 1赵明,包承鑫.组织因子途径抑制物的研究进展[J].中华血液学杂志,1995,16(9):495-497. 被引量:9
  • 2汉建忠.组织因子途径抑制物[J].国外医学(生理病理科学与临床分册),1995,15(1):1-3. 被引量:6
  • 3张庆华,王鸿利.因子Xa依赖的组织因子途径抑制物[J].国外医学(输血及血液学分册),1995,18(4):218-221. 被引量:1
  • 4徐也鲁 王振义 等.止凝血与肿瘤.血栓与止血基础与临床(第二版)[M].上海:上海科学技术出版社,1996.546-554.
  • 5Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol, 2003,43(7):727-734.
  • 6Moatti D,Haidar B,Fumeron F,et al. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haem
  • 7Abraham E,Reinhart K,Svoboda P,et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med, 2001,29(11):20
  • 8Gando S,Nanzaki S,Morimoto Y,et al. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med, 2001,29(2):262-266
  • 9Moatti D,Seknadji P,Galand C,et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Bio
  • 10Kleesiek K,Schmidt M,Gotting C,et al. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost, 1999,82(1):1-5.

共引文献270

同被引文献19

  • 1阮文华,杨永青.急性颅脑损伤颅内出血、脑梗死患者血浆Hcy、NPY、β_2-m和Cor水平的临床意义[J].放射免疫学杂志,2007,20(5):424-426. 被引量:3
  • 2Schick MA,Isbary JT,Stueber T. Effects of crystalloids and colloids on liver and intestine microcirculation and function in cecal ligation and puncture induced septic rodents[J].{H}BMC Gastroenterology,2012,(12):179.
  • 3Levy MM,Fink MP,Marshall JC. 2001 SCCM/ ESICM/ACCP/ AT/ SIS international sepsis definitions conference[J].{H}CRITICAL CARE MEDICINE,2003,(4):1250-1256.
  • 4Yun TH,Monrissey JH. Polyphosphate and omptins:novel bacterial prscoagulant agents[J].{H}Jourmal Cell Mol Med,2009,(10):4146-4153.
  • 5Mosad E,Elsayh KI,Eltayeb AA. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy[J].{H}Clin Appl Thrombosis/Hemostasis,2011,(1):80-87.
  • 6de Jonge E,Dekkers PE,Creasey AA. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia[J].{H}Journal of Infectious Diseases,2001,(12):1815-1818.
  • 7Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis[J].{H}CRITICAL CARE MEDICINE,2000,(9 Suppl):S31-S33.
  • 8Maclaren R,Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome[J].{H}PHARMACOTHERAPY,2007,(6):860-873.
  • 9Hansen JB,Svensson B,Olsen R. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro[J].{H}Thrombosis and Haemostasis,2000,(6):937-943.
  • 10Armstead VE,Opentanova IL,Minchenko AG. Tissue factor expression in vital organs during murine traumatic shock:role of transcription factors AP-1 and NF-kappaB[J].{H}ANESTHESIOLOGY,1999,(6):1844-1852.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部